SEC Form 4 · accession 0000899243-18-006333
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent R Anicetti
Officer — Chief, Quality & Compliance
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | holding | — | — | — | 5,150 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.80 | Mar 1, 2018 | A | 25,000 | A | — | Mar 1, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.